Panoxyvir
Panoxyvir is pioneering a new frontier in antiviral research by transforming physiological molecules produced by the human body into drugs to combat viral infections. The company focuses on oxysterols, cholesterol-derived molecules with strong inhibitory effects against viruses, and has developed cost-effective synthesis methods, formulations, and validated antiviral potential both in vitro and on human respiratory epithelium. Their mission is to develop first-line treatments for rhinovirus infections, especially in cystic fibrosis patients, and to address other viral diseases using oxysterol-based drugs.
Industries
Nr. of Employees
small (1-50)
Panoxyvir
Piazza Giacomo Matteotti n.6, 24122 Bergamo BG, Italy
Products
Oxysterol-based antiviral candidate (preclinical)
A lead oxysterol-derived small-molecule antiviral candidate in preclinical testing targeting rhinovirus infections, with a development plan that includes progression toward regulatory approval using orphan-disease pathways for cystic fibrosis indications. Candidate has demonstrated in vitro and ex vivo antiviral activity.
Oxysterol-based antiviral candidate (preclinical)
A lead oxysterol-derived small-molecule antiviral candidate in preclinical testing targeting rhinovirus infections, with a development plan that includes progression toward regulatory approval using orphan-disease pathways for cystic fibrosis indications. Candidate has demonstrated in vitro and ex vivo antiviral activity.
Services
Laboratory-based antiviral testing and validation services for external biotech and pharmaceutical clients, including standard and mechanistic virology assays, customized virus production, and ex vivo tissue testing. Client retains ownership of compounds and study results according to stated policy.
Laboratory-based antiviral testing and validation services for external biotech and pharmaceutical clients, including standard and mechanistic virology assays, customized virus production, and ex vivo tissue testing. Client retains ownership of compounds and study results according to stated policy.
Expertise Areas
- Antiviral R&D
- Virology assay development and execution
- Preclinical development for respiratory antivirals
- Small-molecule synthesis and formulation (oxysterols)
Key Technologies
- Small-molecule organic synthesis
- Formulation development
- Plaque reduction assays
- Virus yield reduction assays
News & Updates
2nd International Conference on Nanotechnology & Material Science in Kuala Lumpur! Join Us !
Global Health Systems Conference: Innovating for Sustainable Healthcare Kampenhout, Belgium
Research on parvoviruses, particularly human parvovirus B19, including their structure, genome, and applications in biotechnology.
A success story involving research on parvoviruses, highlighting the role of Gentaur Health.
Information on canine brucellosis, its symptoms, diagnosis, treatment, prevention, and public health concerns.
2nd International Conference on Nanotechnology & Material Science in Kuala Lumpur! Join Us !
Global Health Systems Conference: Innovating for Sustainable Healthcare Kampenhout, Belgium
Research on parvoviruses, particularly human parvovirus B19, including their structure, genome, and applications in biotechnology.
A success story involving research on parvoviruses, highlighting the role of Gentaur Health.
Information on canine brucellosis, its symptoms, diagnosis, treatment, prevention, and public health concerns.